Episode Details

FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis Following Vaccination https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-required-updated-warning-labeling-mrna-covid-19-vaccines-regarding-myocarditis-and mRNA COVID Shots Cause Myocarditis (FDA video) Dr Vinay Prasad, Director of the Center for Biologics Evaluation and Research FDA. https://www.youtube.com/watch?v=68QzzWGc4mI June 25, 2025, FDA Safety Communication 6 months through 64 years Approximately 8.4 cases per million doses Initial and follow-up cardiac MRIs commonly showed signs of injury to the heart muscle Males 12 through 24 years Approximately 26.9 cases per million doses, 1/37,000 First reports of C-VAM Feb 2021 (VAERS) April, 2021, 2 deaths and 60 cases from Israel (details sent to FDA and CDC in April 2021) April 27th 2021, DCD statement denies myocarditis signal. April 27th 2021, CDC was aware of 14 cases reported by US military August 2021, FDA document (FOI) 1/5,000 (16 and 17 year old males) Hong Kong, 1 / 2,700 hospitalised (13 to 18 males) Vaccine safety link data, 1 / 2,000 (after 2nd dose in 18 to 24 males) Vaccine safety link data, 64% of cases missed at first First Pfizer booster, 1 / 6,800 Undoubtedly some deaths may be implicated Deaths due to fulminant myocarditis Undoubtedly people have subclinical myocarditis Severe outcomes from covid declining, new risk benefit analysis coming soon. Follow-up information on cardiovascular outcomes From longitudinal retrospective observational study. Most had received a two-dose primary series, prior to diagnosis. Follow-up of approximately 5 months post-vaccination Persistence of abnormal cardiac magnetic resonance imaging (CMR) findings, that are a marker for myocardial injury in 60% of patients. (Late gadolinium enhancement, LGE) Australia data, (at 6 months) 67% LGE and 35% showing fibrosis LGE literature review 92% are men 72% persistent The clinical and prognostic significance of these CMR findings is not known. LGE (from FDA slide) Poor prognostic factor (multiple studies) Associated with increased future cardiac events and mortality 25% admitted to ICU This publication To inform the public and healthcare providers FDA has required and approved updates to the Prescribing Information for Comirnaty (mRNA) manufactured by Pfizer Inc. and Spikevax manufactured ModernaTX, Inc. to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. Required to include information about: (1) the estimated unadjusted incidence of myocarditis and/or pericarditis following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines and (2) the results of a study that collected information on cardiac magnetic resonance imaging (cardiac MRI) in people who developed myocarditis after receiving an mRNA COVID-19 vaccine. Adverse Reactions section of the Prescribing Information and in the Information for Recipients and Caregivers. Based on analyses of commercial health insurance claims data Inpatient and outpatient settings Estimated unadjusted incidence of myocarditis and/or pericarditis (1 through 7 days of the 2023-2024 Formula) In a post-approval U.S. study funded and co-authored by FDA https://www.sciencedirect.com/science/article/pii/S2589537024003882?via%3Dihub Follow-up on approximately 300 people who developed myocarditis Some people in the study reported having heart symptoms approximately 3 months after developing myocarditis. Improvement over time in some but not all people. an mRNA COVID-19 vaccine. These studies are underway. Suspected adverse events may be reported to the Vaccine Adverse Event Reporting System (VAERS), which is co-managed by the FDA and the CDC. https://www

Learn more about your ad choices. Visit megaphone.fm/adchoices